Jefferies Financial Group Inc. Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Jefferies Financial Group acquired a new stake of 170,345 shares in Structure Therapeutics in Q3 (valued at ≈$4.77M), and institutional investors now own about 91.78% of the company.
• Equity analysts have a consensus rating of Moderate Buy with a consensus price target of $107.90, while Jefferies and Morgan Stanley each set a $125 price target and gave bullish ratings.
• Shares opened recently at $56.50 (down ~2.1%), trading in a 52‑week range of $13.22–$94.90 with a market cap of ~$4.0B; the company reported a loss last quarter (EPS -$0.49) and is forecast to post about -$0.82 EPS for the year.

Jefferies Financial Group Inc. bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 170,345 shares of the company's stock, valued at approximately $4,770,000. Jefferies Financial Group Inc. owned 0.30% of Structure Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Rhenman & Partners Asset Management AB raised its holdings in shares of Structure Therapeutics by 33.3% during the third quarter. Rhenman & Partners Asset Management AB now owns 180,100 shares of the company's stock valued at $5,043,000 after buying an additional 45,000 shares during the last quarter. DNB Asset Management AS grew its holdings in Structure Therapeutics by 21.2% in the 3rd quarter. DNB Asset Management AS now owns 12,888 shares of the company's stock worth $361,000 after buying an additional 2,253 shares in the last quarter. Private Capital Advisors Inc. acquired a new stake in Structure Therapeutics in the 3rd quarter valued at approximately $1,545,000. EverSource Wealth Advisors LLC raised its stake in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company's stock valued at $30,000 after acquiring an additional 901 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company's stock worth $114,000 after acquiring an additional 1,146 shares during the period. Institutional investors own 91.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on GPCR shares. Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Citigroup restated an "outperform" rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Wall Street Zen raised shares of Structure Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Morgan Stanley increased their price objective on shares of Structure Therapeutics from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, December 12th. Finally, Jefferies Financial Group set a $125.00 price objective on shares of Structure Therapeutics and gave the company a "buy" rating in a research note on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $107.90.

Structure Therapeutics Trading Down 2.1%

Shares of Structure Therapeutics stock opened at $56.50 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $13.22 and a 52 week high of $94.90. The stock has a market cap of $4.00 billion, a PE ratio of -71.52 and a beta of -1.79. The company's 50-day moving average price is $74.46 and its two-hundred day moving average price is $48.67.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.